- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.11. | Hedge Fund and Insider Trading News: Tom Steyer, David Tepper, Davide Leone, Verition Fund Management, Balyasny Asset Management, Alumis Inc (ALMS), and More | 4 | Insider Monkey | ||
| 13.11. | Alumis reports Q3 results | 7 | Seeking Alpha | ||
| 13.11. | Alumis Inc.: Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress | 367 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| 13.11. | ALUMIS INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11. | ALUMIS INC. - 8-K, Current Report | - | SEC Filings | ||
| ALUMIS Aktie jetzt für 0€ handeln | |||||
| 03.09. | ALUMIS INC. - 8-K, Current Report | 13 | SEC Filings | ||
| 14.08. | Cantor Fitzgerald reiterates Overweight rating on Alumis stock amid post-merger decline | 8 | Investing.com | ||
| 13.08. | Alumis reports Q2 results | 5 | Seeking Alpha | ||
| 13.08. | ALUMIS INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.08. | Schüco Interior Systems: Wird zu Alumis | 7 | MÖBELMARKT | ||
| 04.08. | ALUMIS INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 24.07. | Alumis completes enrollment in lupus treatment phase 2b trial | 4 | Investing.com | ||
| 24.07. | Alumis Inc.: Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus | 391 | GlobeNewswire (Europe) | -Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted... ► Artikel lesen | |
| 14.07. | Alumis promotes Sanam Pangali to chief legal officer | 2 | Investing.com | ||
| 14.07. | Alumis Inc.: Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary | 3 | GlobeNewswire (USA) | ||
| 03.07. | Alumis files $400M mixed securities shelf | 4 | Seeking Alpha | ||
| 29.05. | Alumis Inc.: Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis | 416 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated... ► Artikel lesen | |
| 21.05. | Alumis Inc.: Alumis Completes Merger with ACELYRIN | 454 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated... ► Artikel lesen | |
| 13.05. | ACELYRIN, INC.: ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases | 220 | GlobeNewswire (Europe) | LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines... ► Artikel lesen | |
| 01.05. | ACELYRIN, INC.: ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis | 192 | GlobeNewswire (Europe) | Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 (GLOBE NEWSWIRE) -- ACELYRIN... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,190 | -0,69 % | Rheinmetall Aktie: Sehr spannend! - BioNTech, Evotec, Klöckner, PNE und Stabilus im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| MEDIGENE | 0,025 | -16,11 % | MEDIGENE AG stürzt ab - ich traue meinen Augen nicht! | ||
| QIAGEN | 38,335 | -0,03 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| MODERNA | 25,400 | -0,29 % | Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE | mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the... ► Artikel lesen | |
| VALNEVA | 3,704 | -0,27 % | Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ | IXCHIQ- was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups... ► Artikel lesen | |
| STRYKER | 299,40 | -1,09 % | Medizintechnik-Anbieter Stryker hebt erneut Dividende an | ||
| ILLUMINA | 114,32 | -0,40 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,000 | +0,42 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 640,40 | 0,00 % | 2 Reasons to Buy Regeneron Stock Like There's No Tomorrow | ||
| BRAIN BIOTECH | 2,920 | -0,34 % | EQS-PVR: BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: BRAIN Biotech AG
BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
20.10.2025 / 15:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,388 | +3,06 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy | RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted... ► Artikel lesen | |
| VIKING THERAPEUTICS | 31,210 | +1,36 % | This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street | ||
| BAVARIAN NORDIC | 24,970 | +0,40 % | 5 Aktien mit Kaufsignal, KI killt Aktien, Bavarian Nordic - Neuer AKTIONÄR jetzt im Handel | 5 Aktien mit Kaufsignal, KI killt Aktien, Bavarian Nordic - Neuer AKTIONÄR jetzt im Hande ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,692 | -1,18 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| BIO-GATE | 0,840 | +1,82 % | Bio-Gate: EBITDA verbessert | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC hat die Bio-Gate AG im ersten Halbjahr des Geschäftsjahres 2025 (per 31.12.) mit 3,44 Mio. Euro einen leicht unter Vorjahr... ► Artikel lesen |
ALUMIS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 11,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALUMIS INC finden Sie auf Wallstreet Online.